康德萊醫械(01501.HK)選舉執行董事樑棟科博士為董事長
格隆匯5月16日丨康德萊醫械(01501.HK)公吿,於股東周年大會上,樑棟科博士獲重選為執行董事;林森先生獲委任為執行董事;張維鑫先生及陳紅琴女士獲重選為非執行董事;宋媛博士及王瑞琴先生獲委任為非執行董事;蹇錫高先生及許鴻羣先生獲重選為獨立非執行董事以及徐從禮先生獲委任為獨立非執行董事,作為第三屆董事會成員。第三屆董事會董事的任期自決議案通過之日起至公司於2025年舉行的股東周年大會結束時止。
於緊隨股東周年大會舉行的董事會會議上,董事會一致選舉執行董事樑棟科博士為第三屆董事會董事長。樑棟科博士的任期與其作為執行董事的任期相同。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.